Erythropoiesis stimulating agents have limited therapeutic activity in transfusion‐dependent patients with primary myelofibrosis regardless of serum erythropoietin level
- 2 July 2009
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 83 (2), 154-155
- https://doi.org/10.1111/j.1600-0609.2009.01266.x
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Risk factors for leukemic transformation in patients with primary myelofibrosisCancer, 2008
- Pharmaceutical Erythropoietin Use in Patients With Cancer: Is It Time to Abandon Ship or Just Drop Anchor?Mayo Clinic Proceedings, 2007
- Erythropoietin after a century of research: younger than everEuropean Journal of Haematology, 2007
- Recombinant Human Erythropoietin for the Treatment of Anaemia in Patients with Chronic Idiopathic MyelofibrosisActa Haematologica, 2006
- Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2V617F and response to erythropoietin therapyCancer, 2006
- Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literatureBritish Journal of Haematology, 2004
- Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietinAmerican Journal of Hematology, 2002
- RECOMBINANT HUMAN ERYTHROPOIETIN THERAPY IN PATIENTS WITH MYELOFIBROSIS WITH MYELOID METAPLASIABritish Journal of Haematology, 1994
- Serum erythropoietin in patients with myelofibrosis with myeloid metaplasiaBritish Journal of Haematology, 1993
- Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial [see comments]Blood, 1992